Molecular tumour board in gastrointestinal cancers

被引：0

作者：

Bielo, L. Boscolo ^{[1
,2
]}

Crimini, E. ^{[1
,2
]}

Repetto, M. ^{[3
]}

Barberis, M. ^{[4
]}

Battaiotto, E. ^{[1
,2
]}

Katrini, J. ^{[1
,2
]}

Martino, E. ^{[1
]}

Gaudio, G. ^{[1
]}

Lombardi, M. ^{[4
]}

Zanzottera, C. ^{[5
]}

Aurilio, G. ^{[5
]}

Belli, C. ^{[1
]}

Zhan, Y. ^{[4
]}

Fuorivia, V. ^{[1
,2
]}

Marsicano, R. M. ^{[1
,2
]}

Etessami, J. D. ^{[1
,2
]}

Zagami, P. ^{[1
]}

Marra, A. ^{[1
]}

Trapani, D. ^{[1
,2
]}

Salimbeni, B. Taurelli ^{[1
]}

Criscitiello, C. ^{[1
,2
]}

Ciardiello, D. ^{[6
]}

Lavinia, B. ^{[6
]}

Gervaso, L. ^{[6
]}

Cella, C. A. ^{[6
]}

Spada, F. ^{[6
]}

Zampino, M. G. ^{[6
]}

Fusco, N. ^{[2
,7
]}

Fazio, N. ^{[6
]}

Rocco, E. Guerini ^{[2
,7
]}

Curigliano, G. ^{[1
,2
]}

机构：

[1] European Inst Oncol IRCCS, Early Drug Dev Innovat Therapies, Milan, Italy

[2] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Early Drug Dev Serv, New York, NY USA

[4] European Inst Oncol IRCCS, Dept Expt Oncol, Milan, Italy

[5] European Inst Oncol IEO IRCCS, Div Canc Prevent & Genet, I-20141 Milan, Italy

[6] European Inst Oncol IRCCS, Div Gastrointestinal & Neuroendocrine Tumors Med, IEO, Milan, Italy

[7] European Inst Oncol IRCCS, Div Pathol, IEO, Milan, Italy

来源：

ESMO OPEN | 2025年 / 10卷 / 04期

关键词：

gastrointestinal cancers; molecular tumour board; precision medicine; next-generation sequencing; target therapy; genomic profiling; PRECISION; SURVIVAL;

D O I：

10.1016/j.esmoop.2025.104510

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Comprehensive genomic profiling (CGP) is being increasingly adopted in clinical practice to guide the use of molecularly guided treatment options (MGTOs). To optimize the integration of MGTOs in routine cancer care, molecular tumour boards (MTBs) have been established. Limited data are available to address the clinical value of implementing MTBs to inform treatment decision making in patients with gastrointestinal (GI) cancers. Materials and methods: We retrospectively retrieved medical records from patients with advanced GI cancers discussed at the European Institute of Oncology's MTB between August 2019 and December 2024. We evaluated clinical outcomes resulting from applying MGTOs in cancer care according to MTB recommendations, describing real-world progression-free (rwPFS) and overall survival (OS), and used the growth modulation index (GMI) (ratio of PFSMTB to PFSprior) to quantify the effectiveness of MTB's recommended cancer treatment in extending PFS. Results: Among 192 patients with GI cancers discussed at MTB, 139 (72.3%) received an MTB treatment recommendation. For patients with available follow-up data (n = 82), 31 patients (41.4%, 17.7% overall) received MGTOs, while 51 patients received standard treatments. Patients receiving MGTOs exhibited a longer rwPFS compared with cases receiving standard therapies [5.35 versus 3.55 months, hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.36-1.08, P = 0.08] and with unmatched cases showing actionable biomarkers but not treated with targeted agents (n = 31) (rwPFS 5.35 versus 2.40 months, HR 0.49, 95% CI 0.27-0.90, P = 0.02). The use of MGTOs resulted in a GMI of 1.12 (interquartile range 0.68-2.36). The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) tier I-III treatments resulted in a restricted mean PFS gain of 4.87 months compared with standard therapies (95% CI 1.02-8.72 months, P = 0.01). No OS difference was observed between patients receiving MGTOs and standard treatments (P = 0.89). Conclusions: Our results suggest that MTB-informed clinical decision making could provide valuable clinical benefits and expanded therapeutic options in patients affected by advanced GI cancers.

引用

页数：9

共 44 条

[1]

[Anonymous], Python Software Foundation, https://www.python.org/. Accessed August 1, 2016.

[2] Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study [J].

Bayle, A. ;

Belcaid, L. ;

Aldea, M. ;

Vasseur, D. ;

Peyraud, F. ;

Nicotra, C. ;

Geraud, A. ;

Sakkal, M. ;

Seknazi, L. ;

Cerbone, L. ;

Blanc-Durand, F. ;

Hadoux, J. ;

Mosele, F. ;

Tagliamento, M. ;

Bernard-Tessier, A. ;

Verret, B. ;

Smolenschi, C. ;

Clodion, R. ;

Auger, N. ;

Romano, P. M. ;

Gazzah, A. ;

Camus, M. N. ;

Micol, J. ;

Caron, O. ;

Hollebecque, A. ;

Loriot, Y. ;

Besse, B. ;

Lacroix, L. ;

Rouleau, E. ;

Ponce, S. ;

Soria, J. C. ;

Barlesi, F. ;

Andre, F. ;

Italiano, A. .

ANNALS OF ONCOLOGY, 2023, 34 (04) :389-396

[3] Variant allele frequency: a decision-making tool in precision oncology? [J].

Bielo, Luca Boscolo ;

Trapani, Dario ;

Repetto, Matteo ;

Crimini, Edoardo ;

Valenza, Carmine ;

Belli, Carmen ;

Criscitiello, Carmen ;

Marra, Antonio ;

Subbiah, Vivek ;

Curigliano, Giuseppe .

TRENDS IN CANCER, 2023, 9 (12) :1058-1068

[4] Molecular tumor board in patients with metastatic breast cancer [J].

Boscolo Bielo, Luca ;

Guerini Rocco, Elena ;

Crimini, Edoardo ;

Repetto, Matteo ;

Lombardi, Mariano ;

Zanzottera, Cristina ;

Aurilio, Gaetano ;

Barberis, Massimo ;

Belli, Carmen ;

Zhan, Yinxiu ;

Battaiotto, Elena ;

Katrini, Jalissa ;

Marsicano, Renato ;

Zagami, Paola ;

Taurelli Salimbeni, Beatrice ;

Esposito, Angela ;

Trapani, Dario ;

Criscitiello, Carmen ;

Fusco, Nicola ;

Marra, Antonio ;

Curigliano, Giuseppe .

BREAST CANCER RESEARCH AND TREATMENT, 2025, 210 (01) :45-55

[5] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer [J].

Boscolo Bielo, Luca ;

Trapani, Dario ;

Curigliano, Giuseppe .

EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) :789-801

[6]

Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011

[7]

Chandran A, 2018, SPRINGER THESES-RECO, P1, DOI 10.1007/978-981-10-6547-7_1

[8]

Ddsjoberg, GitHub-ddsjoberg/gtsummary: Presentation-ready data summary and analytic result tables

[9] ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2-ABC) with aggressive disease criteria [J].

de la Haba Rodriguez, J. ;

Cortes, J. ;

Di Cosimo, S. ;

Lopez-Barajas, I. Blancas ;

Cortez Castedo, S. P. ;

Lopez, A. ;

Lopez-Miranda, E. ;

Pla Juher, H. ;

Albacar Miro, C. R. ;

Ponce, J. ;

Caranana Ballerini, V. ;

Paris Bouzas, L. ;

Valero Arbizu, M. ;

Ruiz Borrego, M. R. B. ;

Iranzo, V. ;

Garrido, A. ;

Alcala-Lopez, D. ;

Mina, L. ;

Garcia Mosquera, J. J. ;

Llombart Cussac, A. .

ANNALS OF ONCOLOGY, 2024, 35 :1215-1216

[10] The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit [J].

Esposito, Angela ;

Crimini, Edoardo ;

Criscitiello, Carmen ;

Belli, Carmen ;

Scafetta, Roberta ;

Scalia, Raimondo ;

Castellano, Grazia ;

Giordano, Elisa ;

Katrini, Jalissa ;

Ascione, Liliana ;

Boscolo Bielo, Luca ;

Repetto, Matteo ;

Marra, Antonio ;

Trapani, Dario ;

Varano, Gianluca Maria ;

Maiettini, Daniele ;

Della Vigna, Paolo ;

Orsi, Franco ;

Guerini Rocco, Elena ;

Fusco, Nicola ;

Curigliano, Giuseppe .

CANCERS, 2024, 16 (24)

← 1 2 3 4 5 →